HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Best treatment for small HER-2–positive, node-negative breast cancers unknown
• Is trastuzumab plus endocrine therapy sufficient for patients who are triple positive but node negative, or do they also require chemotherapy? Halle Moore, MD; Edward H. Romond, MD
• ‘Conflict of interest’ outdated phrase for physician-industry relationship?
• Contraindicated enoxaparin, eptifibatide linked with increased risk for bleeding, mortality in dialysis patients undergoing PCI
• KRAS identification, TOGA trial results make 2009 a big year for gastrointestinal cancer research
• NIH examines DCIS data; issues new recommendations
• RE-LY, ACTIVE offer options for reducing stroke risk in patients with AF
• Is the paradigm wrong? Alan P. Venook, MD; Anne M. Espinoza, MD
• A winter journey
• Administrative issues plague patient access schemes in Britain
• Age affected coping strategies among patients with sickle cell disease
• Exposure to higher levels of endogenous hormones associated with increased breast cancer risk
• HPV vaccines decreased the risk for variety of HPV–related diseases
• Office of Oncology Drug Products approved 53 of 60 applications in 2.5 years
• PICU catheter-associated bloodstream infections can be reduced with proper maintenance
• Preventive tamoxifen use low in 2000, 2005
• FACT: Addition of fulvestrant to anastrozole showed no advantage for breast cancer
• ITPC results incomplete; no link between CYP2D6 and tamoxifen outcome
• Lapatinib plus trastuzumab improved OS in HER-2–positive metastatic breast cancer
• Radiotherapy and tamoxifen benefitted women with locally excised DCIS
• Somatostatin imaging added no diagnostic information to CT, MRI for neuroendocrine tumors
• Ofatumumab in the treatment of patients with chronic lymphocytic leukemia Lisa K. Lohr, PharmD, BCPS, BCOP